Skip to main content
placeholder image

Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia

Journal Article


Abstract


  • Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008���2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ���18��years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6��months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan���Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24���2.37 and OR 1.47, 95% CI 1.17���1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7���93.8) and were not hospitalised (93.1%, 95% CI 92.1���94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.

Publication Date


  • 2019

Citation


  • Tervonen, H. E., Chen, T. Y. T., Lin, E., Boyle, F. M., Moylan, E. J., Della-Fiorentina, S. A., . . . Currow, D. C. (2019). Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia. European Journal of Cancer Care, 28(5). doi:10.1111/ecc.13125

Scopus Eid


  • 2-s2.0-85067835902

Volume


  • 28

Issue


  • 5

Place Of Publication


Abstract


  • Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008���2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ���18��years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6��months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan���Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24���2.37 and OR 1.47, 95% CI 1.17���1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7���93.8) and were not hospitalised (93.1%, 95% CI 92.1���94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.

Publication Date


  • 2019

Citation


  • Tervonen, H. E., Chen, T. Y. T., Lin, E., Boyle, F. M., Moylan, E. J., Della-Fiorentina, S. A., . . . Currow, D. C. (2019). Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia. European Journal of Cancer Care, 28(5). doi:10.1111/ecc.13125

Scopus Eid


  • 2-s2.0-85067835902

Volume


  • 28

Issue


  • 5

Place Of Publication